RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline Acquisition will add novel long-acting GLP-1 with plans...
CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial RALEIGH, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a...
Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships Continued activities of the first Phase 3 clinical trial for celiac disease including...
Innovate undertakes succession planning for a chief executive officer Finance team strengthened and well positioned for future growth Second quarter earnings release expected August 8, 2019...
RALEIGH, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune...
RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune...
Analyst Meeting to be held at 4:30pm ET today to discuss NASH data and provide clinical updates Three posters presented at DDW 2019 highlighted the protective effect and molecular mechanism of...
RALEIGH, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for...
RALEIGH, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced the closing of its previously announced registered direct offering of 4,318,272...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.